HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Emma Bolderson Selected Research

Therapeutics

1/2024Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.
1/2024The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth.
9/2023Mono-phosphorylation at Ser4 of barrier-to-autointegration factor (Banf1) significantly reduces its DNA binding capability by inducing critical changes in its local conformation and DNA binding surface.
1/2023hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
12/2022The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy.
9/2021Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer.
1/2021Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy.
1/2021Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy.
1/2021Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer.
1/2021Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Emma Bolderson Research Topics

Disease

14Neoplasms (Cancer)
04/2024 - 06/2006
12Genomic Instability
01/2023 - 05/2008
7Ataxia Telangiectasia (Louis Bar Syndrome)
01/2023 - 12/2004
4Lung Neoplasms (Lung Cancer)
12/2023 - 01/2020
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2021 - 10/2020
3Breast Neoplasms (Breast Cancer)
01/2024 - 05/2014
3Progeria (Hutchinson Gilford Syndrome)
01/2021 - 12/2014
2Triple Negative Breast Neoplasms
01/2024 - 05/2014
2Adenocarcinoma
09/2021 - 10/2020
2Chromosomal Instability (Chromosome Stability)
04/2010 - 08/2009
2Hypersensitivity (Allergy)
04/2010 - 08/2009
1Colorectal Neoplasms (Colorectal Cancer)
01/2024
1Cicatrix (Scar)
01/2023
1Prostatic Neoplasms (Prostate Cancer)
01/2023
1Xeroderma Pigmentosum (Kaposi's Disease)
10/2021
1Premature Aging
01/2021
1Ovarian Neoplasms (Ovarian Cancer)
01/2020
1Chromosome Aberrations (Chromosome Abnormalities)
06/2014
1Familial Breast Cancer
05/2014
1Genetic Translocation (Chromosomal Translocation)
01/2014

Drug/Important Bio-Agent (IBA)

18Proteins (Proteins, Gene)FDA Link
01/2024 - 10/2009
15DNA (Deoxyribonucleic Acid)IBA
09/2023 - 12/2004
6Phosphotransferases (Kinase)IBA
01/2023 - 12/2004
41,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
01/2023 - 04/2010
4PlatinumIBA
09/2021 - 01/2020
3Messenger RNA (mRNA)IBA
04/2024 - 01/2016
3Biomarkers (Surrogate Marker)IBA
01/2021 - 05/2014
3ChromatinIBA
01/2021 - 08/2012
3Cisplatin (Platino)FDA LinkGeneric
01/2021 - 01/2020
3DNA-Binding Proteins (DNA Binding Protein)IBA
04/2013 - 05/2008
2Small Interfering RNA (siRNA)IBA
01/2024 - 11/2016
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2021 - 10/2009
2chloropyramineIBA
10/2020 - 11/2016
2Indicators and Reagents (Reagents)IBA
10/2020 - 08/2009
2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2020 - 10/2009
1Aurora Kinase BIBA
01/2024
1Fluorouracil (Carac)FDA LinkGeneric
01/2024
1Hormones (Hormone)IBA
01/2024
13,3,5,5-tetramethyl-1-pyrroline N-oxide (TMPO)IBA
01/2024
1emerinIBA
01/2024
1Androgen Receptors (Androgen Receptor)IBA
01/2023
1Glucose (Dextrose)FDA LinkGeneric
01/2023
1DNA-Activated Protein KinaseIBA
01/2023
1AndrogensIBA
01/2023
1Transcription Factors (Transcription Factor)IBA
01/2023
1Tyrosine Kinase InhibitorsIBA
09/2021
1ErbB Receptors (EGF Receptor)IBA
09/2021
1Cytotoxins (Cytolysins)IBA
01/2021
1Carboplatin (JM8)FDA LinkGeneric
01/2021
1lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2020
1NucleophosminIBA
01/2016
1Alanine (L-Alanine)FDA Link
12/2014
1Threonine (L-Threonine)FDA Link
12/2014
1CamptothecinIBA
06/2014
1HeterochromatinIBA
08/2012
1Co-Repressor ProteinsIBA
08/2012
1human EXO1 proteinIBA
04/2010
1Antineoplastic Agents (Antineoplastics)IBA
10/2009
1Carrier Proteins (Binding Protein)IBA
10/2009
1dimemorfan (AT 17)IBA
06/2006
1Ataxia Telangiectasia Mutated ProteinsIBA
12/2004

Therapy/Procedure

15Therapeutics
01/2024 - 10/2009
7Drug Therapy (Chemotherapy)
01/2024 - 10/2009
3Immunotherapy
01/2021 - 01/2020
1Radiotherapy
01/2023